Sensei Biotherapeutics Inc
$ 30.22
-11.71%
26 Feb - close price
- Market Cap 43,187,500 USD
- Current Price $ 30.22
- High / Low $ 34.52 / 27.60
- Stock P/E N/A
- Book Value 18.24
- EPS -19.14
- Next Earning Report 2026-03-27
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.37 %
- ROE -0.70 %
- 52 Week High 36.76
- 52 Week Low 5.00
About
Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, is dedicated to the discovery and development of therapies with an initial focus on cancer treatments. The company is headquartered in Rockville, Maryland.
Analyst Target Price
$32.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-14 | 2025-08-05 | 2025-05-07 | 2025-02-26 | 2024-11-05 | 2024-08-06 | 2024-05-09 | 2024-02-28 | 2023-11-07 | 2023-08-03 | 2023-05-09 | 2023-03-28 |
| Reported EPS | -3.62 | -3.91 | -0.2725 | -0.2728 | -0.29 | -0.28 | -0.32 | -0.3 | -0.28 | -0.31 | -0.33 | -0.4 |
| Estimated EPS | -0.23 | -0.24 | -0.26 | -0.29 | -0.31 | -0.29 | -0.28 | -0.31 | -0.34 | -0.33 | -0.36 | -0.4 |
| Surprise | -3.39 | -3.67 | -0.0125 | 0.0172 | 0.02 | 0.01 | -0.04 | 0.01 | 0.06 | 0.02 | 0.03 | 0 |
| Surprise Percentage | -1473.913% | -1529.1667% | -4.8077% | 5.931% | 6.4516% | 3.4483% | -14.2857% | 3.2258% | 17.6471% | 6.0606% | 8.3333% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-27 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -4.81 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SNSE
2026-02-25 10:53:36
Sensei Biotherapeutics announced inducement grants of options to purchase 2,319,893 shares of its common stock to 17 new employees, effective February 19, 2026, under Nasdaq Listing Rule 5635(c)(4). This includes a grant to Anand Parikh, the new Chief Operating Officer, for 1,239,305 shares. The options have an exercise price of $27.22 and will vest over four years, with 25% vesting on the first anniversary and the remainder in equal monthly installments over the subsequent three years.
2026-02-23 00:27:47
Sensei Biotherapeutics has acquired Faeth Therapeutics and secured a private placement expected to generate US$200 million. Sidley Austin LLP advised Sensei Biotherapeutics on this transaction. The article indicates that full details are only accessible to standard members.
2026-02-20 13:33:41
Sensei Biotherapeutics, Inc. filed a Form 3 SEC report, indicating that Parikh Anand Kiran has been added as an insider. He is identified as both a director and the Chief Operating Officer of the company. This Form 3 is an initial statement of beneficial ownership and does not report any stock transactions or specific share amounts, simply establishing his status as a reporting person under SEC rules for insiders.
2026-02-19 19:29:39
Sensei Biotherapeutics has completed its stock-for-stock acquisition of Faeth Therapeutics, making Faeth a wholly owned subsidiary and adding its PIKTOR asset to Sensei's oncology pipeline. This deal significantly alters Sensei’s cap table, with former Faeth equityholders and new investors holding the majority. Concurrent with the acquisition, Sensei also secured a private placement of Series B preferred stock expected to raise approximately $200 million and made key leadership changes.
2026-02-19 04:53:36
Sensei Biotherapeutics (SNSE) expanded its board of directors from three to five members, appointing Christopher W. Gerry and Phillip B. Donenberg as new directors. These appointments are expected to enhance the company's governance with significant legal and financial expertise. An analyst rating on SNSE stock is currently a Hold with a $9.00 price target, though TipRanks' AI Analyst, Spark, rates it as Neutral due to weak fundamentals, financing risk, and valuation constraints despite positive technicals.
2026-02-18 23:37:31
Sensei Biotherapeutics (NASDAQ:SNSE) saw its stock surge by 230% following the announcement of its acquisition of Faeth Therapeutics and a simultaneous $200 million private investment. The acquisition adds Faeth's lead asset, PIKTOR, an investigational therapy for solid tumors, to Sensei's pipeline. The private placement will fund PIKTOR through key clinical milestones, including a Phase 2 trial in endometrial cancer and a Phase 1b trial in breast cancer.
